One example of this is the high-quality retrospective analysis of randomized phase three clinical trial data sets, which led to the routine clinical use of KRAS as a biomarker for response to anti-EGFR therapies in colorectal cancer [114, 115]. Here, EGFR is linked to colorectal cancer.